The White House has reportedly backed away from nominating a pharmaceutical executive to run the U.S. Trademark and Patent Office after critics alleged he was unlikely to take a firm enough stance against frivolous patent suits.
Tech website Gigaom reports that the White House has backed away from naming Johnson & Johnson’s chief patent attorney, Philip Johnson, as Director of the USPTO. The prospective appointment raised eyebrows in tech circles as critics pointed to his near decade-long record of opposition to patent reform, which many in the tech sector say is badly needed.
Johnson has represented Coalition for 21st Century Patent Reform, an industry group which successfully lobbied against several legislative overhauls to the patent system. The group has frequently locked horns with technology companies, which have pressed lawmakers to crack down on frivolous patent infringement lawsuits.
Sen. Charles Schumer opposed Johnson’s nomination in an emailed statement to the Wall Street Journal, saying that Johnson was “unsympathetic” to the proliferation of patent lawsuits by so-called “patent trolls,” particularly within the tech industry.
The top position at the USPTO has remained vacant since its previous director, David Kappos, stepped down last year.
- Succession Was a Race to the Bottom, And Everybody Won
- What Erdoğan’s Victory Means for Turkey—and the World
- Why You Can't Remember That Taylor Swift Concert All Too Well
- How Four Trans Teens Threw the Prom of Their Dreams
- Why Turkey’s Longtime Leader Is an Electoral Powerhouse
- The Ancient Roots of Psychotherapy
- Drought Crisis Spurs U.S.-Mexico Collaboration
- Florence Pugh Might Just Save the Movie Star From Extinction